A glycosyltransferase and its application in glycosylation reaction

By optimizing the amino acid sequence and nucleotide sequence of glycosyltransferase, combining expression vectors and host cell design, the catalytic activity and stability of stevia glycosides are improved, and the problems of low efficiency and poor stability of stevia-derived enzymes are solved, and stevia is realized Efficient industrial production of glycosides.

CN118755692BActive Publication Date: 2024-11-19SICHUAN INGIA BIOSYNTHETIC CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411245574.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-19
Estimated Expiration
2044-09-06

AI Technical Summary

Technical Problem

The catalytic activity of stevia-derived glycosyltransferases is limited, has low conversion efficiency, is not suitable for industrial production, and is sensitive to environmental conditions and has poor stability, which limits the efficient industrial production of stevia glycosides.

Method used

A series of glycosyltransferases and their mutants are provided, including UGT91G201 and its mutant sites, such as V91A, Y93W, D131N, F133H, M200F, V206M, H359W, F381A, which improves the amino acid sequence and nucleotide sequence by optimizing the amino acid sequence and nucleotide sequence. Catalytic activity and stability, and the design of expression vectors and host cells, an efficient glycosylation reaction is achieved.

Benefits of technology

The newly discovered glycosyltransferase and its mutants show good catalytic activity and specificity in the process of catalyzing steviol glycosides D and M, and are more stable, suitable for industrial production, which solves the efficiency and stability of steviol glycoside production. Sexual problems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention relates to the field of biotechnology, and in particular to a glycosyltransferase and its application in a glycosylation reaction. The present invention provides a glycosyltransferase and its mutants and their application in catalytic synthesis of steviol glycosides, solving the technical problems that the catalytic activity of stevia-derived glycosyltransferase is limited, the conversion efficiency is low, and it is not conducive to industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to a glycosyltransferase and an application thereof in a glycosylation reaction. Background Art

[0002] Glycosylation is an important biochemical process in organisms, involving the transfer of sugar molecules (sugar groups) from activated glycosyl donors (such as UDP-glucose) to acceptor molecules through the action of specific enzymes to form stable glycosidic bonds. Glycosylation can occur on many types of biological molecules, including proteins, lipids, and nucleic acids, adding additional structure and function to these molecules. In glycosylation reactions, glycosyltransferases play a vital role. Glycosyltransferases are a class of enzymes with high substrate specificity that can recognize and catalyze the transfer of sugars from activated glycosyl donors to acceptor molecules. The activity and specificity of these enzymes are crucial to the efficiency of glycosylation reactions and the accuracy of the products, which in turn affects the metabolism and function of the entire organism.

[0003] Steviosides are a series of natural low-calorie sweeteners extracted from stevia and widely used in the food and beverage industry. These sweeteners, mainly including rebaudioside A and rebaudioside D, are ideal for diabetics and people who want to lose weight because of their sweetness hundreds of times that of sucrose and their almost energy-free properties. As consumers pursue a healthy lifestyle, the application of steviol glycosides is becoming more and more diverse. In the production of steviol glycosides, glycosyltransferases play a vital role. By catalyzing specific glycosylation reactions, sugar molecules are accurately added to the steviol skeleton to generate sweet glycosides. However, the catalytic activity of stevia-derived glycosyltransferases is limited and the conversion efficiency is low, which to some extent limits their application in industrial production. Existing enzymes are sensitive to environmental conditions, and stability issues and cost-effectiveness considerations have also become technical challenges that restrict their widespread application. Therefore, improving the catalytic efficiency and stability of glycosyltransferases is the key to achieving efficient industrial production of steviol glycosides. Summary of the invention

[0004] In view of this, the present invention provides a series of glycosyltransferases, which solve the technical problems that the glycosyltransferases derived from stevia have limited catalytic activity, low conversion efficiency and are not conducive to industrial production.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides a glycosyltransferase having:

[0007] (1) the amino acid sequence shown in SEQ ID NO: 1; or

[0008] (2) An amino acid sequence obtained by substituting, deleting or adding one or more residues of the amino acid sequence shown in (1), and having the same or similar function as (1); or

[0009] (3) An amino acid sequence that is at least 90% homologous to the amino acid sequence shown in (1) or (2).

[0010] The present invention also provides a nucleic acid molecule having a nucleotide sequence encoding the above glycosyltransferase.

[0011] In some specific embodiments of the present invention, the nucleotide sequence of the above nucleic acid molecule comprises:

[0012] (4) the nucleotide sequence shown in SEQ ID NO: 2; or

[0013] (5) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (4), and having the same or similar function as (4); or

[0014] (6) A nucleotide sequence having at least 90% homology with the nucleotide sequence shown in (4) or (5).

[0015] The present invention also provides a mutant of the above-mentioned glycosyltransferase, wherein the mutation site is at least one of V91A, Y93W, D131N, F133H, I158K, M200F, V206M, H359W, and F381A.

[0016] In some specific embodiments of the present invention, the mutation site of the mutant includes any of the following:

[0017] V91A and F133H; or

[0018] V91A and M200F; or

[0019] Y93W and V206M; or

[0020] F133H and V206M; or

[0021] V91A, F133H and V206M; or

[0022] V91A, F133H and F381A; or

[0023] V91A, Y93W, F133H and V206M; or

[0024] V91A, F133H, M200F and V206M; or

[0025] V91A, D131N, F133H and V206M; or

[0026] V91A, Y93W, D131N and V206M; or

[0027] V91A, Y93W, F133H, M200F and V206M; or

[0028] V91A, D131N, F133H, V206M and F381A; or

[0029] V91A, F133H, M200F, V206M and F381A; or

[0030] V91A, Y93W, F133H, M200F, V206M and F381A; or

[0031] V91A, D131N, F133H, M200F, V206M, and F381A; or

[0032] V91A, Y93W, D131N, F133H, M200F, V206M and F381A.

[0033] The present invention also provides a nucleic acid molecule having a nucleotide sequence encoding the mutant.

[0034] In some specific embodiments of the present invention, the nucleotide sequence encoding the mutant in the above-mentioned nucleic acid molecule includes any of the following:

[0035] V91A: SEQ ID NO: 2 in which GTG at positions 271 to 273 is replaced by GCA; or

[0036] Y93W: SEQ ID NO: 2 wherein TAC at positions 277 to 279 is replaced by TGG; or

[0037] D131N: SEQ ID NO: 2 in which GAT at positions 391 to 393 is replaced by AAC; or

[0038] F133H: SEQ ID NO: 2 wherein TTC at positions 397 to 399 is replaced by CAC; or

[0039] I158K: SEQ ID NO: 2 wherein ATC at positions 472-474 is replaced by AAA; or

[0040] M200F: SEQ ID NO: 2, wherein ATG at positions 598 to 600 is replaced by TTC; or

[0041] V206M: SEQ ID NO: 2 in which GTG at positions 616 to 618 are replaced by ATG; or

[0042] H359W: SEQ ID NO: 2 wherein CAC at positions 1075-1077 is replaced by TGG; or

[0043] F381A: SEQ ID NO: 2 wherein TTT at positions 1141-1143 is replaced by GCC; or

[0044] V91A and F133H: SEQ ID NO: 2, wherein GTG at positions 271 to 273 is replaced by GCA, and TTC at positions 397 to 399 is replaced by CAC; or

[0045] V91A and M200F: SEQ ID NO: 2, wherein GTG at positions 271 to 273 is replaced by GCA, and ATG at positions 598 to 600 is replaced by TTC; or

[0046] Y93W and V206M: SEQ ID NO: 2, wherein TAC at positions 277 to 279 is replaced by TGG, and GTG at positions 616 to 618 is replaced by ATG; or

[0047] F133H and V206M: SEQ ID NO: 2, wherein TTC at positions 397 to 399 is replaced by CAC, and GTG at positions 616 to 618 is replaced by ATG; or

[0048] V91A, F133H and V206M: SEQ ID NO: 2, wherein GTG at positions 271-273 is replaced by GCA, TTC at positions 397-399 is replaced by CAC, and GTG at positions 616-618 is replaced by ATG; or

[0049] V91A, F133H and F381A: SEQ ID NO: 2, wherein GTG at positions 271-273 is replaced by GCA, TTC at positions 397-399 is replaced by CAC, and TTT at positions 1141-1143 is replaced by GCC; or

[0050] V91A, Y93W, F133H and V206M: SEQ ID NO: 2, wherein GTG at positions 271-273 is replaced by GCA, TAC at positions 277-279 is replaced by TGG, TTC at positions 397-399 is replaced by CAC, and GTG at positions 616-618 is replaced by ATG; or

[0051] V91A, F133H, M200F and V206M: SEQ ID NO: 2 in which GTG at positions 271-273 is replaced by GCA, TTC at positions 397-399 is replaced by CAC, ATG at positions 598-600 is replaced by TTC, and GTG at positions 616-618 is replaced by ATG; or

[0052] V91A, D131N, F133H and V206M: SEQ ID NO: 2, wherein GTG at positions 271-273 is replaced by GCA, GAT at positions 391-393 is replaced by AAC, TTC at positions 397-399 is replaced by CAC, and GTG at positions 616-618 is replaced by ATG; or

[0053] V91A, Y93W, D131N and V206M: SEQ ID NO: 2, wherein GTG at positions 271-273 is replaced by GCA, TAC at positions 277-279 is replaced by TGG, GAT at positions 391-393 is replaced by AAC, and GTG at positions 616-618 is replaced by ATG; or

[0054] V91A, Y93W, F133H, M200F and V206M: SEQ ID NO: 2 in which GTG at positions 271-273 are replaced by GCA, TAC at positions 277-279 are replaced by TGG, TTC at positions 397-399 are replaced by CAC, ATG at positions 598-600 are replaced by TTC, and GTG at positions 616-618 are replaced by ATG; or

[0055] V91A, D131N, F133H, V206M and F381A: SEQ ID NO: 2 wherein GTG at positions 271-273 is replaced by GCA, GAT at positions 391-393 is replaced by AAC, TTC at positions 397-399 is replaced by CAC, GTG at positions 616-618 is replaced by ATG, and TTT at positions 1141-1143 is replaced by GCC; or

[0056] V91A, F133H, M200F, V206M and F381A: SEQ ID NO: 2 in which GTG at positions 271-273 are replaced by GCA, TTC at positions 397-399 are replaced by CAC, ATG at positions 598-600 are replaced by TTC, GTG at positions 616-618 are replaced by ATG, and TTT at positions 1141-1143 are replaced by GCC; or

[0057] V91A, Y93W, F133H, M200F, V206M and F381A: SEQ ID NO: 2 in which GTG at positions 271-273 are replaced by GCA, TAC at positions 277-279 are replaced by TGG, TTC at positions 397-399 are replaced by CAC, ATG at positions 598-600 are replaced by TTC, GTG at positions 616-618 are replaced by ATG, and TTT at positions 1141-1143 are replaced by GCC; or

[0058] V91A, D131N, F133H, M200F, V206M and F381A: SEQ ID NO: 2 in which GTG at positions 271-273 are replaced by GCA, GAT at positions 391-393 are replaced by AAC, TTC at positions 397-399 are replaced by CAC, ATG at positions 598-600 are replaced by TTC, GTG at positions 616-618 are replaced by ATG, and TTT at positions 1141-1143 are replaced by GCC; or

[0059] V91A, Y93W, D131N, F133H, M200F, V206M and F381A: SEQ ID NO: 2 in which GTG at positions 271-273 are replaced by GCA, TAC at positions 277-279 are replaced by TGG, GAT at positions 391-393 are replaced by AAC, TTC at positions 397-399 are replaced by CAC, ATG at positions 598-600 are replaced by TTC, GTG at positions 616-618 are replaced by ATG, and TTT at positions 1141-1143 are replaced by GCC.

[0060] The present invention also provides an expression vector having any of the following:

[0061] (a1), the above-mentioned nucleic acid molecule having a nucleotide sequence encoding the above-mentioned glycosyltransferase;

[0062] (a2), the above-mentioned nucleic acid molecule having a nucleotide sequence encoding the above-mentioned mutant;

[0063] (a3), the nucleic acid molecule having the nucleotide sequence encoding the glycosyltransferase, and the gene element expressing UGT76G1;

[0064] (a4), the nucleic acid molecule having the nucleotide sequence encoding the mutant, and the gene element expressing UGT76G1.

[0065] In some specific embodiments of the present invention, the backbone of the above expression vector is pETDuet-1.

[0066] The present invention also provides an expression vector combination, comprising the above expression vector and an expression vector for expressing AtSUS1.

[0067] In some specific embodiments of the present invention, the above expression vector is combined with the expression vector for expressing AtSUS1, and its backbone is pRSFDuet-1.

[0068] The present invention also provides a host cell having any of the following:

[0069] (b1), the above-mentioned nucleic acid molecule having a nucleotide sequence encoding the above-mentioned glycosyltransferase;

[0070] (b2), the above-mentioned nucleic acid molecule having a nucleotide sequence encoding the above-mentioned mutant;

[0071] (b3), the above-mentioned expression vector;

[0072] (b4) The above expression vector combination.

[0073] In some specific embodiments of the present invention, the host cell is a bacterium;

[0074] The bacteria include Escherichia coli.

[0075] The present invention also provides a method for preparing glycosyltransferase, which is prepared based on any of the following:

[0076] (c1), the above-mentioned nucleic acid molecule having a nucleotide sequence encoding the above-mentioned glycosyltransferase;

[0077] (c2) the above-mentioned nucleic acid molecule having a nucleotide sequence encoding the above-mentioned mutant;

[0078] (c3), the above-mentioned expression vector;

[0079] (c4), the above expression vector combination;

[0080] (c5) The above-mentioned host cell, wherein the host cell includes Escherichia coli.

[0081] The present invention also provides the use of any of the following in the preparation of steviol glycosides:

[0082] (d1), the above-mentioned glycosyltransferase;

[0083] (d2), the above mutants;

[0084] (d3), glycosyltransferase prepared according to the above preparation method;

[0085] The steviol glycosides include Reb D and / or Reb M.

[0086] The present invention also provides a method for preparing steviol glycoside, comprising: preparing steviol glycoside based on the above host cell;

[0087] The reaction system prepared comprises:

[0088] 0.1 g / mL, 0.15 g / mL, 0.2 g / mL, 0.25 g / mL or 0.3 g / mL of the above host cells;

[0089] 55 mM, 56 mM, 57 mM, 58 mM, 59 mM, 60 mM, 61 mM, 62 mM, 63 mM, 64 mM, or 65 mM trisodium citrate;

[0090] 95 mM, 96 mM, 97 mM, 98 mM, 99 mM, 100 mM, 101 mM, 102 mM, 103 mM, 104 mM or 105 mM sodium phosphate buffer at pH 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5;

[0091] 0.05mM, 0.06mM, 0.07mM, 0.08mM, 0.09mM, 0.1mM, 0.11mM, 0.12mM, 0.13mM, 0.14mM or 0.15mM MgCl2;

[0092] 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5% (v / v) xylene;

[0093] 350 g / L, 360 g / L, 370 g / L, 380 g / L, 390 g / L, 400 g / L, 410 g / L, 420 g / L, 430 g / L, 440 g / L or 450 g / L sucrose;

[0094] 55 g / L, 56 g / L, 57 g / L, 58 g / L, 59 g / L, 60 g / L, 61 g / L, 62 g / L, 63 g / L, 64 g / L or 65 g / L substrate;

[0095] The temperature of the conversion is 38°C, 39°C, 40°C, 41°C or 42°C;

[0096] The conversion time is 12 h, 18 h, 24 h, 30 h, 36 h, 48 h, 54 h, 60 h, 66 h or 72 h;

[0097] The substrate includes Reb A;

[0098] The steviol glycosides include Reb D and / or Reb M.

[0099] The glycosyltransferase of the present invention and its mutant have the following effects:

[0100] The newly discovered glycosyltransferase and its mutation-optimized variants, compared with the glycosyltransferase derived from stevia leaves, show good catalytic activity and strong specificity in the process of catalyzing the synthesis of steviol glycosides D and M, and have stronger stability. DETAILED DESCRIPTION

[0101] The present invention discloses a glycosyltransferase and its application in a glycosylation reaction. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0102] The present invention provides a glycosyltransferase UGT91G201, which is sourced from Puccinellia tenuiflora and has an amino acid sequence as shown in SEQ ID NO: 1;

[0103] The codon-optimized nucleic acid sequence of Escherichia coli is shown in SEQ ID NO: 2.

[0104] The present invention also provides a mutant of the glycosyltransferase UGT91G201, wherein the mutation sites include: V91A, Y93W, D131N, F133H, I158K, M200F, V206M, H359W, and F381A.

[0105] This application protects single point mutations and multiple point mutations.

[0106] The sequence information involved in the present invention is as follows:

[0107] UGT91G201, derived from Puccinellia tenuiflora, amino acid (protein) sequence SEQ ID NO: 1:

[0108] MENSSSSSSSSSAPLHVVICPWLAFGHLLPCLDLAERLASRGHRVSYVSTPRNLARLPPVRPIVAPLVDFVALPLPHVEGLPEGAESTNDVPYEKFELHRKAFDGLAGPFSEFLGAACAEGGKKPDWIIVDVFHHWAAAAAIEHKVPCAMLVLAAASITAIWAANVAKQAASWEGQPAAGTPRFEVERRKLATTQRASGMSVAERVTLTLQRCDLVVIRSCLEWEPESVPLLATLGGKPVVPLGLLPPSPEGGRGVVSKDGKDATLIWLDAQPAKSVVYVALGSEVPLSVEQVHELAVGLELAGTRFLWALRKPSGVPDADVLPPGFEERTRGRGLVVTGWVPQISVLAHGAVGAFLTHCGWNSTIEGLLFGHPLIMLPIFGDQGPNARLMEGREVGVQVPRIENDGSFGRDGVATAVRTVAVEEESRRIFAANAKKMQEIVHDSECHERCIDGFIQRLRSHKE;

[0109] Escherichia coli codon-optimized nucleic acid sequence SEQ ID NO: 2:

[0110]

[0111] The primer sequence information involved in the present invention is shown in Table 1.

[0112] Table 1: Primer design

[0113]

[0114] EUGT11, from rice ( Oryza sativa Japonica Group), amino acid (protein) sequence accession number is GenBank: AAS07253;

[0115] E. coli codon-optimized nucleic acid sequence SEQ ID NO: 35:

[0116]

[0117] AtSUS1, from Arabidopsis thaliana, amino acid (protein) sequence accession number is GenBank: QKZ93247;

[0118] E. coli codon-optimized nucleic acid sequence SEQ ID NO: 36:

[0119]

[0120] UGT76G1 is derived from Stevia rebaudiana, and the amino acid (protein) sequence accession number is GenBank: QTI50358;

[0121] E. coli codon-optimized nucleic acid sequence SEQ ID NO: 37:

[0122]

[0123] Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all common commercial products and can be purchased from the market.

[0124] The present invention will be further described below in conjunction with the embodiments.

[0125] Example 1

[0126] 1. Cloning of glycosyltransferase and sucrose synthase genes

[0127] UGT91G201, AtSUS1, UGT76G1, and EUGT11 were codon-optimized for E. coli, and full-length DNA sequences were synthesized.

[0128] 2. Construction of recombinant expression vector

[0129] Using pETDuet-1 as the expression vector, the In-Fusion strategy was used to construct a recombinant expression plasmid. PCR amplification primers containing homology arms were designed (see Table 1) to clone UGT91G201 and the linearized pETDuet-1 vector. According to the instructions of the kit, the DNA fragment and the linearized vector fragment were subjected to homologous recombination reaction. After reacting at 50 degrees for 1 hour, the competent cells of E. coli DH5α were transformed and coated with Amp-resistant plates and cultured overnight at 37 degrees. Positive clones were screened by colony PCR, and positive clones were picked and placed in 5 mL LB medium containing Amp for sequencing verification. The recombinant plasmid pETDuet-1-UGT91G201 with correct sequencing was extracted.

[0130] Using the same scheme as above, PCR amplification primers containing homology arms were designed (see Table 1) to clone UGT76G1 and the linearized pETDuet-1-UGT91G201 recombinant vector, and the recombinant plasmid pETDuet-1-UGT91G201-UGT76G1 was obtained using the same homologous recombination strategy as above.

[0131] Using pRSFDuet-1 as the expression vector, the In-Fusion strategy was used to construct a recombinant expression plasmid. PCR amplification primers containing homology arms were designed (see Table 1) to clone AtSUS1 and the linearized pRSFDuet-1 recombinant vector. According to the instructions of the kit, the DNA fragment and the linearized vector fragment were subjected to homologous recombination reaction. After reacting at 50 degrees for 1 hour, the competent cells of E. coli DH5α were transformed and coated with Kan resistance plates and cultured overnight at 37 degrees. Positive clones were screened by colony PCR, and positive clones were picked in 5 mL LB medium containing Kan for sequencing verification, and the recombinant plasmid pRSFDuet-1-AtSUS1 with correct sequencing was extracted.

[0132] Using pETDuet-1 as the expression vector, the In-Fusion strategy was used to construct a recombinant expression plasmid. PCR amplification primers containing homology arms were designed (see Table 1) to clone EUGT11 and the linearized pETDuet-1 vector. According to the instructions of the kit, the DNA fragment and the linearized vector fragment were subjected to homologous recombination reaction. After reacting at 50 degrees for 1 hour, the competent cells of E. coli DH5α were transformed and coated with Kan resistance plates and cultured overnight at 37 degrees. Positive clones were screened by colony PCR, and positive clones were picked and placed in 5 mL LB medium containing Kan for sequencing verification. The recombinant plasmid pETDuet-1-EUGT11 (control example) with correct sequencing was extracted.

[0133] Using the same scheme as above, PCR amplification primers containing homology arms were designed (see Table 1) to clone UGT76G1 and the linearized pETDuet-1-EUGT11 recombinant vector, and the recombinant plasmid pETDuet-1-EUGT11-UGT76G1 (control example) was obtained using the same homologous recombination strategy as above.

[0134] 3. UGT91G201 mutant construction method: plasmid loop p mutation.

[0135] Take the V91A single point mutation as an example:

[0136] Using pETDuet-1-UGT91G201 as a template, mutant primers were designed (primers are shown in Table 1) and PCR amplification was performed. The PCR product was digested with restriction endonuclease Dpn I for 2 h to remove the template; the target band was recovered after agarose gel electrophoresis, eluted with ddH2O, and then transformed into E. coli DH5α competent cells, coated with Amp-resistant plates and cultured at 37°C overnight; colony PCR was used to screen positive clones, and positive clones were picked in 5 mL LB medium containing Amp, sequenced and verified, and the correct plasmid pETDuet-1-UGT91G201 (V91A) was extracted.

[0137] The remaining plasmid construction methods were the same as the V91A single point mutation, and the primers were shown in Table 1. The plasmids obtained were as follows:

[0138] pETDuet-1-UGT91G201 (Y93W);

[0139] pETDuet-1-UGT91G201 (D131N);

[0140] pETDuet-1-UGT91G201 (F133H);

[0141] pETDuet-1-UGT91G201 (I158K);

[0142] pETDuet-1-UGT91G201 (M200F);

[0143] pETDuet-1-UGT91G201 (V206M);

[0144] pETDuet-1-UGT91G201 (H359W);

[0145] pETDuet-1-UGT91G201 (F381A);

[0146] pETDuet-1-UGT91G201 (V91A / F133H);

[0147] pETDuet-1-UGT91G201 (V91A / M200F);

[0148] pETDuet-1-UGT91G201 (Y93W / V206M);

[0149] pETDuet-1-UGT91G201 (F133H / V206M);

[0150] pETDuet-1-UGT91G201 (V91A / F133H / V206M);

[0151] pETDuet-1-UGT91G201 (V91A / F133H / F381A);

[0152] pETDuet-1-UGT91G201 (V91A / Y93W / F133H / V206M);

[0153] pETDuet-1-UGT91G201 (V91A / F133H / M200F / V206M);

[0154] pETDuet-1-UGT91G201 (V91A / D131N / F133H / V206M);

[0155] pETDuet-1-UGT91G201 (V91A / Y93W / D131N / V206M);

[0156] pETDuet-1-UGT91G201 (V91A / Y93W / F133H / M200F / V206M);

[0157] pETDuet-1-UGT91G201 (V91A / D131N / F133H / V206M / F381A);

[0158] pETDuet-1-UGT91G201 (V91A / F133H / M200F / V206M / F381A);

[0159] pETDuet-1-UGT91G201 (V91A / Y93W / F133H / M200F / V206M / F381A);

[0160] pETDuet-1-UGT91G201 (V91A / D131N / F133H / M200F / V206M / F381A);

[0161] pETDuet-1-UGT91G201 (V91A / Y93W / D131N / F133H / M200F / V206M / F381A).

[0162] Using pETDuet-1-UGT91G201-UGT76G1 as a template, mutant primers were designed (primers are shown in Table 1) and PCR amplification was performed. The PCR product was digested with restriction endonuclease Dpn I for 2 h to remove the template; the target band was recovered after agarose gel electrophoresis, eluted with ddH2O during recovery, and then transformed into E. coli DH5α competent cells, coated with Amp-resistant plates and cultured at 37°C overnight; colony PCR was used to screen positive clones, and positive clones were picked in 5 mL LB medium containing Amp, sequenced and verified, and the correct plasmid pETDuet-1-UGT91G201 (V91A)-UGT76G1 was extracted.

[0163] The construction methods of the remaining plasmids were the same as pETDuet-1-UGT91G201 (V91A)-UGT76G1. The primers are shown in Table 1. The plasmids obtained were as follows:

[0164] pETDuet-1-UGT91G201 (Y93W)-UGT76G1;

[0165] pETDuet-1-UGT91G201 (D131N)-UGT76G1;

[0166] pETDuet-1-UGT91G201 (F133H)-UGT76G1;

[0167] pETDuet-1-UGT91G201 (I158K)-UGT76G1;

[0168] pETDuet-1-UGT91G201 (M200F)-UGT76G1;

[0169] pETDuet-1-UGT91G201 (V206M)-UGT76G1;

[0170] pETDuet-1-UGT91G201 (H359W)-UGT76G1;

[0171] pETDuet-1-UGT91G201 (F381A)-UGT76G1;

[0172] pETDuet-1-UGT91G201 (V91A / F133H)-UGT76G1;

[0173] pETDuet-1-UGT91G201 (V91A / M200F)-UGT76G1;

[0174] pETDuet-1-UGT91G201 (Y93W / V206M)-UGT76G1;

[0175] pETDuet-1-UGT91G201 (F133H / V206M)-UGT76G1;

[0176] pETDuet-1-UGT91G201 (V91A / F133H / V206M)-UGT76G1;

[0177] pETDuet-1-UGT91G201 (V91A / F133H / F381A)-UGT76G1;

[0178] pETDuet-1-UGT91G201 (V91A / Y93W / F133H / V206M)-UGT76G1;

[0179] pETDuet-1-UGT91G201 (V91A / F133H / M200F / V206M)-UGT76G1;

[0180] pETDuet-1-UGT91G201 (V91A / D131N / F133H / V206M)-UGT76G1;

[0181] pETDuet-1-UGT91G201 (V91A / Y93W / D131N / V206M)-UGT76G1;

[0182] pETDuet-1-UGT91G201 (V91A / Y93W / F133H / M200F / V206M)-UGT76G1;

[0183] pETDuet-1-UGT91G201 (V91A / D131N / F133H / V206M / F381A)-UGT76G1;

[0184] pETDuet-1-UGT91G201 (V91A / F133H / M200F / V206M / F381A)-UGT76G1;

[0185] pETDuet-1-UGT91G201 (V91A / Y93W / F133H / M200F / V206M / F381A)-UGT76G1;

[0186] pETDuet-1-UGT91G201 (V91A / D131N / F133H / M200F / V206M / F381A)-UGT76G1;

[0187] pETDuet-1-UGT91G201 (V91A / Y93W / D131N / F133H / M200F / V206M / F381A)-UGT76G1.

[0188] 4. Construction of recombinant expression bacteria

[0189] (1) Construction of Reb D-producing recombinant expression strains STE-RD01 to STE-RD25

[0190] Take the recombinant expression bacteria STE-RD01 as an example:

[0191] The recombinant plasmids pETDuet-1-UGT91G201 and pRSFDuet-1-AtSUS1 constructed above were co-transformed into E. coli BL21 (DE3) to obtain recombinant strains, which were frozen in a -80°C refrigerator for future use.

[0192] The frozen recombinant strain was inoculated into 5-10 mL of LB medium containing Amp and Kan resistance, and cultured at 37°C overnight to prepare the fermentation seed solution. The seed solution was inoculated into 50 mL of TB medium at a 1% inoculation rate, and cultured at 200 rpm at 37°C until OD 600 When the p-value reached 0.6-0.8, 0.1 mM IPTG was added and the expression was induced at 22℃ for 24 h. Then, the recombinant expression bacteria STE-RD01 were collected by centrifugation at 12,000 rpm and 4℃ and stored at -20℃ for future use.

[0193] The construction and preparation methods of the remaining recombinant expression bacteria containing the UGT91G201 mutant were the same as those of the recombinant expression bacteria STE-RD01, and the recombinant expression bacteria STE-RD02 to STE-RD25 were obtained respectively.

[0194] (2) Construction of control example STE-RD00

[0195] The recombinant plasmids pETDuet-1-EUGT11 and pRSFDuet-1-AtSUS1 constructed above were co-transformed into E. coli BL21 (DE3) to obtain a recombinant strain, which was frozen in a -80°C refrigerator for future use. Then, the recombinant expression strain STE-RD00 was constructed using the same method as the recombinant expression strain STE-RD01 and stored at -20°C for future use.

[0196] Table 2

[0197]

[0198] (3) Construction of Reb M-producing recombinant expression strains STE-RM01 to STE-RM25

[0199] Take the recombinant expression bacteria STE-RM01 as an example

[0200] The recombinant plasmids pETDuet-1-UGT91G201-UGT76G1 and pRSFDuet-1-AtSUS1 constructed in step 3 were co-transformed into E. coli BL21 (DE3) to obtain a recombinant strain, which was frozen in a -80°C refrigerator for future use.

[0201] The frozen recombinant strain was inoculated into 5-10 mL of LB medium containing Amp and Kan resistance, and cultured at 37°C overnight to prepare the fermentation seed solution. The seed solution was inoculated into 50 mL of TB medium at a 1% inoculation rate, and cultured at 200 rpm at 37°C until OD 600 When the p-value reached 0.6-0.8, 0.1 mM IPTG was added and the expression was induced at 22℃ for 24 h. Then, the recombinant expression bacteria STE-RM01 were collected by centrifugation at 12,000 rpm and 4℃ and stored at -20℃ for future use.

[0202] The construction and preparation methods of the remaining recombinant expression bacteria containing the UGT91G201 mutant were the same as those of the recombinant expression bacteria STE-RM01, and the recombinant expression bacteria STE-RM02 to STE-RM25 were obtained respectively.

[0203] (4) Construction of control example STE-RM00

[0204] The recombinant plasmids pETDuet-1-EUGT11-UGT76G1 and pRSFDuet-1-AtSUS1 constructed above were co-transformed into E. coli BL21 (DE3) to obtain a recombinant strain, which was frozen in a -80°C refrigerator for future use. Then, the recombinant expression strain STE-RM00 was constructed using the same method as the recombinant expression strain STE-RM01 and stored at -20°C for future use.

[0205] Table 3

[0206]

[0207] Example 2

[0208] 1. Verification and comparison of single enzyme activity

[0209] The recombinant plasmids pETDuet-1-UGT91G201 and pETDuet-1-EUGT11 were transferred into E. coli BL21 (DE3) to obtain recombinant strains D01 and D02, which were frozen in a -80°C refrigerator. The frozen strains D01 and D02 were inoculated into 5-10 mL of LB medium containing Amp resistance and cultured at 37°C overnight to prepare fermentation seed liquid; the seed liquid was inoculated into 50 mL of TB medium at a 1% inoculation amount and cultured at 200 rpm at 37°C until OD 600 When the p value reached 0.6-0.8, 0.1 mM IPTG was added and the expression was induced at 22℃ for 24 h. Then, the cells were collected by centrifugation at 12,000 rpm and 4℃ and stored at -20℃ for later use.

[0210] The cells were resuspended in 100 mM pH 7.0 PBS buffer, and a final concentration of 1 mM PMSF and 1 mg / mL lysozyme were added, and stirred on ice for 30 min; the cells were disrupted by ultrasound, the supernatant was collected by centrifugation, incubated with the Ni-NTA affinity column for 40-60 min, and the effluent was removed; then the impurities and the target protein were eluted with 100 mM pH 7.0 PBS buffer containing different concentrations of imidazole (20 mM, 250 mM); the target protein was replaced with buffer, dialyzed, desalted and concentrated using an ultrafiltration tube, and then aliquoted and stored at -80°C for later use.

[0211] Enzyme activity test system: 200 μL volume includes 20 mM pH 7.5 Tris-HCl buffer, 0.5 mM substrate RA, 1 mM UDPG and 2 μg glycosyltransferase UGT91G201 or EUGT11, reaction temperature is 37℃, reaction time is 2 h, and each set of reaction conditions is repeated 3 times. After the reaction is completed, an equal volume of methanol is added to quench, centrifuged at 12,000 rpm for 10 min to remove the precipitate, and the supernatant is filtered through a 0.22 μm filter membrane for HPLC analysis.

[0212] The HPLC detection conditions were: isocratic 33% acetonitrile-67% phosphoric acid water (pH 3.0), detection wavelength of 210 nm, and column temperature of 40°C. The content of Reb D in the reaction sample was determined, and the conversion rate of Reb D was calculated. The detection results are shown in Table 4.

[0213] Table 4: Comparison of single enzymes

[0214]

[0215] From the test results, it can be seen that the single enzyme activity of UGT91G201 is higher than that of EUGT11, and the conversion rate is significantly improved.

[0216] 2. Stability test of recombinant expression bacteria

[0217] The recombinant plasmids of the UGT91G201 mutant described in Example 1 were sequentially transferred into E. coli BL21 (DE3) to obtain recombinant strains D03 to D26, which were frozen in a -80°C refrigerator. The frozen strains D03 to D26 were inoculated into 5 to 10 mL of LB medium containing Amp resistance, and cultured at 37°C overnight to prepare fermentation seed liquid; the seed liquid was inoculated into 50 mL of TB medium at a 1% inoculation amount, and cultured at 200 rpm at 37°C until OD 600 When the p value reached 0.6-0.8, 0.1 mM IPTG was added and the expression was induced at 22℃ for 24 h. Then, the cells were collected by centrifugation at 12,000 rpm and 4℃ and stored at -20℃ for later use.

[0218] The D03~D26 bacteria were resuspended in 100 mM pH 7.0 PBS buffer, and a final concentration of 1 mM PMSF and 1 mg / mL lysozyme were added, and stirred on ice for 30 min; the cells were disrupted by ultrasound, the supernatant was collected by centrifugation, incubated with the Ni-NTA affinity column for 40~60 min, and the effluent was removed; then the impurities and the target protein were eluted with 100 mM pH 7.0 PBS buffer containing different concentrations of imidazole (20 mM, 250 mM); the target protein was replaced with buffer, dialyzed, desalted and concentrated using an ultrafiltration tube, and then stored at -80℃ for later use after aliquoting.

[0219] The purified enzyme solution was diluted to the same protein concentration with 20 mM pH 7.5 Tris-HCl buffer and kept in a 65°C water bath for different time periods. The relative residual enzyme activity was determined according to the standard method and the half-life (t 1 / 2 ), the test results are shown in Table 5.

[0220] Table 5: Stability test

[0221]

[0222] 3. Whole-cell biotransformation reaction experimental verification

[0223] 1) Experimental verification of biotransformation reaction of recombinant bacteria producing Reb D

[0224] The recombinant expression bacteria STE-RD00 to STE-RD25 obtained in Example 1 were resuspended and washed twice with 100 mM sodium phosphate buffer at pH 8.0 to obtain wet bacteria, which were used for whole-cell catalytic reaction to verify their conversion rate.

[0225] The biotransformation reaction system is:

[0226] 0.2 g / mL wet bacteria, 60 mM trisodium citrate, 100 mM sodium phosphate buffer at pH 8.0, 0.1 mMMgCl2, 1% (v / v) xylene, 400 g / L sucrose and 60 g / L substrate Reb A, reaction temperature 40°C, reaction time 24h. After the reaction, an equal volume of methanol was added to quench, centrifuged at 12,000 rpm for 10 min to remove the precipitate, and the supernatant was filtered through a 0.22 μm filter membrane for HPLC analysis.

[0227] The HPLC detection conditions were: isocratic 33% acetonitrile-67% phosphoric acid water (pH 3.0), detection wavelength of 210 nm, and column temperature of 40°C. The contents of Reb A and Reb D in the reaction samples were determined, and the conversion rate of Reb D was calculated. The detection results are shown in Table 6.

[0228] Table 6: Biotransformation

[0229]

[0230] 2) Experimental verification of biotransformation reaction of recombinant bacteria producing Reb M

[0231] The recombinant expression cells STE-RM00 to STE-RM25 obtained in Example 1 were resuspended and washed twice with 100 mM sodium phosphate buffer at pH 8.0 to obtain wet cells, which were used for whole-cell catalytic reaction to verify their conversion rate.

[0232] The biotransformation reaction system is:

[0233] 0.2 g / mL wet bacteria, 60 mM trisodium citrate, 100 mM sodium phosphate buffer at pH 8.0, 0.1 mMMgCl2, 1% (v / v) xylene, 400 g / L sucrose and 60 g / L substrate Reb A, reaction temperature 40°C, reaction time 24h. After the reaction, an equal volume of methanol was added to quench, centrifuged at 12,000 rpm for 10 min to remove the precipitate, and the supernatant was filtered through a 0.22 μm filter membrane for HPLC analysis.

[0234] The HPLC detection conditions were: isocratic 33% acetonitrile-67% phosphoric acid water (pH 3.0), detection wavelength of 210 nm, and column temperature of 40°C. The contents of Reb A, Reb D, and Reb M in the reaction samples were determined, and the conversion rate of Reb M was calculated. The detection results are shown in Table 7.

[0235] Table 7: Biotransformation

[0236]

[0237] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A glycosyltransferase, characterized in that The sequence is the sequence shown in SEQ ID NO:

1.

2. A nucleic acid molecule, characterized in that The sequence is a nucleotide sequence encoding the glycosyltransferase according to claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that The nucleotide sequence is SEQ ID NO:

2.

4. The mutant of glycosyltransferase according to claim 1, characterized in that The mutation sites are: Y93W; or D131N; or F133H; or I158K; or M200F; or V206M; or H359W; or F381A; or V91A and F133H; or V91A and M200F; or Y93W and V206M; or F133H and V206M; or V91A, F133H and V206M; or V91A, F133H and F381A; or V91A, Y93W, F133H and V206M; or V91A, F133H, M200F and V206M; or V91A, D131N, F133H and V206M; or V91A, Y93W, D131N and V206M; or V91A, Y93W, F133H, M200F and V206M; or V91A, D131N, F133H, V206M and F381A; or V91A, F133H, M200F, V206M and F381A; or V91A, Y93W, F133H, M200F, V206M and F381A; or V91A, D131N, F133H, M200F, V206M, and F381A; or V91A, Y93W, D131N, F133H, M200F, V206M and F381A.

5. A nucleic acid molecule, characterized in that Having a nucleotide sequence encoding the mutant according to claim 4.

6. An expression vector, characterized in that Have any of the following: (a1), the nucleic acid molecule according to claim 2 or 3; (a2), the nucleic acid molecule according to claim 5; (a3), a nucleic acid molecule according to claim 2 or 3 and a genetic element for expressing UGT76G1; (a4), the nucleic acid molecule as described in claim 5 and the genetic element expressing UGT76G1.

7. A host cell, excluding a totipotent cell, characterized in that Have any of the following: (b1), the nucleic acid molecule according to claim 2 or 3; (b2), the nucleic acid molecule according to claim 5; (b3) The expression vector according to claim 6.

8. A method for preparing a glycosyltransferase, characterized in that: Prepared based on any of the following: (c1), the nucleic acid molecule according to claim 2 or 3; (c2), the nucleic acid molecule according to claim 5; (c3) The expression vector according to claim 6; (c4) The host cell according to claim 7.

9. Use of any of the following in the preparation of Reb D or Reb M: (d1), the glycosyltransferase according to claim 1; (d2), the mutant according to claim 4; (d3) Glycosyltransferase prepared according to the preparation method of claim 8.

10. A method for preparing Reb D or Reb M, characterized in that include: Producing Reb D or Reb M based on the host cell of claim 7; The prepared reaction system comprises: 0.1-0.3 g / mL of the host cell according to claim 7, 55-65 mM trisodium citrate, 95-105 mM sodium phosphate buffer with a pH of 7.5-8.5, 0.05-0.15 mM MgCl2, 0.5%-1.5% (v / v) xylene, 350-450 g / L sucrose and 55-65 g / L Reb A; The preparation temperature is 38-42°C; The preparation time is 12 to 72 hours.